CN107427507A - 呼吸器官感染治疗剂 - Google Patents
呼吸器官感染治疗剂 Download PDFInfo
- Publication number
- CN107427507A CN107427507A CN201680015197.3A CN201680015197A CN107427507A CN 107427507 A CN107427507 A CN 107427507A CN 201680015197 A CN201680015197 A CN 201680015197A CN 107427507 A CN107427507 A CN 107427507A
- Authority
- CN
- China
- Prior art keywords
- infection
- fluoro
- therapeutic agent
- respiratory apparatus
- cyclopropylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 102
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 100
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims abstract description 52
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims abstract description 51
- 235000019253 formic acid Nutrition 0.000 claims abstract description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 12
- 239000011737 fluorine Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 91
- 150000001875 compounds Chemical class 0.000 claims description 83
- 241000894006 Bacteria Species 0.000 claims description 82
- 229940124597 therapeutic agent Drugs 0.000 claims description 65
- 210000001519 tissue Anatomy 0.000 claims description 39
- 244000052769 pathogen Species 0.000 claims description 38
- 230000001717 pathogenic effect Effects 0.000 claims description 38
- 206010035664 Pneumonia Diseases 0.000 claims description 29
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims description 29
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 206010059866 Drug resistance Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 241000194017 Streptococcus Species 0.000 claims description 21
- 206010006451 bronchitis Diseases 0.000 claims description 21
- 230000001684 chronic effect Effects 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 20
- 201000008197 Laryngitis Diseases 0.000 claims description 16
- 201000007100 Pharyngitis Diseases 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 241000191940 Staphylococcus Species 0.000 claims description 15
- 206010042566 Superinfection Diseases 0.000 claims description 15
- 206010044008 tonsillitis Diseases 0.000 claims description 14
- 210000002821 alveolar epithelial cell Anatomy 0.000 claims description 11
- 230000036470 plasma concentration Effects 0.000 claims description 11
- 241000606768 Haemophilus influenzae Species 0.000 claims description 9
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 9
- 208000025301 tympanitis Diseases 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000588621 Moraxella Species 0.000 claims description 4
- 201000009240 nasopharyngitis Diseases 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000220304 Prunus dulcis Species 0.000 claims 2
- 235000020224 almond Nutrition 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- -1 methoxyl group Chemical group 0.000 abstract description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 abstract description 2
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical compound FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 abstract 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 44
- 210000004072 lung Anatomy 0.000 description 37
- 238000012360 testing method Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 229960001699 ofloxacin Drugs 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 241000191967 Staphylococcus aureus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 150000007660 quinolones Chemical class 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 210000001132 alveolar macrophage Anatomy 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 229960003405 ciprofloxacin Drugs 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010054814 DNA Gyrase Proteins 0.000 description 3
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229940041033 macrolides Drugs 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108020003631 Kinetoplast DNA Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 101150070420 gyrA gene Proteins 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- PCFUWBOSXMKGIP-UHFFFAOYSA-N 2-benzylpyridine Chemical compound C=1C=CC=NC=1CC1=CC=CC=C1 PCFUWBOSXMKGIP-UHFFFAOYSA-N 0.000 description 1
- OQDXZZHGQBFAKM-UHFFFAOYSA-N 2-fluoropyrrolidine Chemical compound FC1CCCN1 OQDXZZHGQBFAKM-UHFFFAOYSA-N 0.000 description 1
- WDGCBNTXZHJTHJ-UHFFFAOYSA-N 2h-1,3-oxazol-2-id-4-one Chemical class O=C1CO[C-]=N1 WDGCBNTXZHJTHJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- DJXNJVFEFSWHLY-ZQBYOMGUSA-N N1=[14CH]C(=CC2=CC=CC=C12)C(=O)O Chemical compound N1=[14CH]C(=CC2=CC=CC=C12)C(=O)O DJXNJVFEFSWHLY-ZQBYOMGUSA-N 0.000 description 1
- SMWDFEZZVXVKRB-WGGUOBTBSA-N N1=[14CH]C=CC2=CC=CC=C12 Chemical compound N1=[14CH]C=CC2=CC=CC=C12 SMWDFEZZVXVKRB-WGGUOBTBSA-N 0.000 description 1
- 206010049592 Peritonsillitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UOBPHQJGWSVXFS-UHFFFAOYSA-N [O].[F] Chemical compound [O].[F] UOBPHQJGWSVXFS-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 101150059798 grlA gene Proteins 0.000 description 1
- 101150097244 grxC2 gene Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QZFXTAVCZYQMQZ-HTRCEHHLSA-N n-[[(3r,4s)-4-fluoropyrrolidin-3-yl]methyl]cyclopropanamine Chemical class F[C@@H]1CNC[C@@H]1CNC1CC1 QZFXTAVCZYQMQZ-HTRCEHHLSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 101150110811 parC gene Proteins 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- SKIBYTHWQPTZMX-UHFFFAOYSA-N phenyl 3-oxopropanoate Chemical class O=CCC(=O)OC1=CC=CC=C1 SKIBYTHWQPTZMX-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 208000011437 staphylococcus aureus pneumonia Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111531689.7A CN113975277A (zh) | 2015-03-13 | 2016-03-11 | 呼吸器官感染治疗剂 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015051206 | 2015-03-13 | ||
JP2015-051206 | 2015-03-13 | ||
JP2015-136944 | 2015-07-08 | ||
JP2015136944 | 2015-07-08 | ||
PCT/JP2016/057797 WO2016148066A1 (ja) | 2015-03-13 | 2016-03-11 | 呼吸器感染症治療剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111531689.7A Division CN113975277A (zh) | 2015-03-13 | 2016-03-11 | 呼吸器官感染治疗剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107427507A true CN107427507A (zh) | 2017-12-01 |
CN107427507B CN107427507B (zh) | 2021-12-17 |
Family
ID=56920174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111531689.7A Pending CN113975277A (zh) | 2015-03-13 | 2016-03-11 | 呼吸器官感染治疗剂 |
CN201680015197.3A Active CN107427507B (zh) | 2015-03-13 | 2016-03-11 | 呼吸器官感染治疗剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111531689.7A Pending CN113975277A (zh) | 2015-03-13 | 2016-03-11 | 呼吸器官感染治疗剂 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20180042918A1 (zh) |
EP (1) | EP3269369A4 (zh) |
JP (1) | JP6077725B1 (zh) |
KR (1) | KR102532681B1 (zh) |
CN (2) | CN113975277A (zh) |
AU (1) | AU2016234411C1 (zh) |
BR (1) | BR112017019205A2 (zh) |
CA (1) | CA2978261A1 (zh) |
EA (1) | EA201791995A1 (zh) |
IL (1) | IL253878A0 (zh) |
MX (1) | MX2017011040A (zh) |
MY (1) | MY191848A (zh) |
PH (1) | PH12017501505A1 (zh) |
SG (2) | SG10201908007UA (zh) |
WO (1) | WO2016148066A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201911826VA (en) * | 2017-06-16 | 2020-01-30 | Kyorin Pharmaceutical Co Ltd | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
EA202090066A1 (ru) * | 2018-03-30 | 2020-04-15 | Керин Фармасьютикал Ко., Лтд. | Терапевтическое средство для лечения аспирационной пневмонии, легочного нагноения или абсцесса легких |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1222151A (zh) * | 1996-04-24 | 1999-07-07 | 第一制药株式会社 | 环烷基氨甲基吡咯烷衍生物 |
CN1653071A (zh) * | 2002-03-18 | 2005-08-10 | 杏林制药株式会社 | 对耐药菌有效的10-(3-环丙基氨基甲基-1-吡咯烷基)吡啶并苯并噁嗪羧酸衍生物 |
CN1849316A (zh) * | 2003-09-10 | 2006-10-18 | 杏林制药株式会社 | 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物 |
WO2013145750A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
CN103930414A (zh) * | 2011-11-10 | 2014-07-16 | 杏林制药株式会社 | 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 |
WO2014174848A1 (ja) * | 2013-04-25 | 2014-10-30 | 杏林製薬株式会社 | 錠剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007027618A1 (de) | 2007-06-12 | 2008-12-18 | Rehau Ag + Co | Verfahren zur Vorbehandlung von zu lackierenden polymeren Oberflächen |
-
2016
- 2016-03-11 AU AU2016234411A patent/AU2016234411C1/en not_active Ceased
- 2016-03-11 SG SG10201908007U patent/SG10201908007UA/en unknown
- 2016-03-11 BR BR112017019205-5A patent/BR112017019205A2/pt not_active Application Discontinuation
- 2016-03-11 JP JP2016553614A patent/JP6077725B1/ja active Active
- 2016-03-11 KR KR1020177028859A patent/KR102532681B1/ko active IP Right Grant
- 2016-03-11 MY MYPI2017703082A patent/MY191848A/en unknown
- 2016-03-11 SG SG11201706951XA patent/SG11201706951XA/en unknown
- 2016-03-11 EP EP16764896.3A patent/EP3269369A4/en not_active Withdrawn
- 2016-03-11 EA EA201791995A patent/EA201791995A1/ru unknown
- 2016-03-11 MX MX2017011040A patent/MX2017011040A/es unknown
- 2016-03-11 CN CN202111531689.7A patent/CN113975277A/zh active Pending
- 2016-03-11 US US15/554,329 patent/US20180042918A1/en not_active Abandoned
- 2016-03-11 CA CA2978261A patent/CA2978261A1/en not_active Abandoned
- 2016-03-11 WO PCT/JP2016/057797 patent/WO2016148066A1/ja active Application Filing
- 2016-03-11 CN CN201680015197.3A patent/CN107427507B/zh active Active
-
2017
- 2017-08-07 IL IL253878A patent/IL253878A0/en unknown
- 2017-08-18 PH PH12017501505A patent/PH12017501505A1/en unknown
-
2018
- 2018-11-13 US US16/189,461 patent/US10918634B2/en active Active
-
2020
- 2020-11-05 US US17/090,218 patent/US20210052572A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1222151A (zh) * | 1996-04-24 | 1999-07-07 | 第一制药株式会社 | 环烷基氨甲基吡咯烷衍生物 |
CN1116295C (zh) * | 1996-04-24 | 2003-07-30 | 第一制药株式会社 | 环烷基氨甲基吡咯烷衍生物 |
CN1653071A (zh) * | 2002-03-18 | 2005-08-10 | 杏林制药株式会社 | 对耐药菌有效的10-(3-环丙基氨基甲基-1-吡咯烷基)吡啶并苯并噁嗪羧酸衍生物 |
CN1849316A (zh) * | 2003-09-10 | 2006-10-18 | 杏林制药株式会社 | 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物 |
CN100410249C (zh) * | 2003-09-10 | 2008-08-13 | 杏林制药株式会社 | 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物 |
CN103930414A (zh) * | 2011-11-10 | 2014-07-16 | 杏林制药株式会社 | 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 |
WO2013145750A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
WO2014174848A1 (ja) * | 2013-04-25 | 2014-10-30 | 杏林製薬株式会社 | 錠剤 |
Non-Patent Citations (11)
Title |
---|
ASAHINA, YOSHIKAZU: "Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
何权瀛: "《呼吸内科诊疗常规》", 30 November 2012, 中国医药科技出版社 * |
李典友 等: "《特禽高效养殖与产品深加工新技术》", 28 February 2013, 金盾出版社 * |
段虹等: "《实用健康体检学》", 30 June 2014, 陕西科学技术出版社 * |
满江 等: "《对症艾灸妙治百病》", 30 September 2014, 青岛出版社 * |
王传新: "《现代检验医学技术及质量控制》", 30 April 2004, 山东科学技术出版社 * |
王林贵: "《袖珍检验手册》", 30 April 1997, 河北科学技术出版社 * |
董火林等: "《现代胸部疾病急症学》", 30 June 1999, 四川科学技术出版社 * |
邹栩 等: "《1984-1996世界上市新药》", 31 December 1996, 中国药科大学期刊编辑部 * |
马亦林等: "《传染病学 第5版》", 31 May 2011, 上海科学技术出版社 * |
马宁生: "《儿科护理学》", 31 August 2007, 同济大学出版社 * |
Also Published As
Publication number | Publication date |
---|---|
IL253878A0 (en) | 2017-10-31 |
CN107427507B (zh) | 2021-12-17 |
AU2016234411C1 (en) | 2020-04-30 |
EP3269369A4 (en) | 2018-11-07 |
AU2016234411A1 (en) | 2017-09-07 |
KR20170123695A (ko) | 2017-11-08 |
JPWO2016148066A1 (ja) | 2017-04-27 |
EA201791995A1 (ru) | 2017-12-29 |
KR102532681B1 (ko) | 2023-05-15 |
MX2017011040A (es) | 2017-11-10 |
AU2016234411B2 (en) | 2020-01-30 |
PH12017501505B1 (en) | 2018-02-05 |
JP6077725B1 (ja) | 2017-02-08 |
BR112017019205A2 (pt) | 2018-04-24 |
US20190076421A1 (en) | 2019-03-14 |
CA2978261A1 (en) | 2016-09-22 |
WO2016148066A1 (ja) | 2016-09-22 |
CN113975277A (zh) | 2022-01-28 |
US10918634B2 (en) | 2021-02-16 |
EP3269369A1 (en) | 2018-01-17 |
SG10201908007UA (en) | 2019-10-30 |
MY191848A (en) | 2022-07-18 |
US20180042918A1 (en) | 2018-02-15 |
PH12017501505A1 (en) | 2018-02-05 |
US20210052572A1 (en) | 2021-02-25 |
SG11201706951XA (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2826473B1 (en) | Antibacterial use of patchoulol | |
CN108570032B (zh) | 新型罗丹明染料及其在抗致病菌中的应用 | |
CN101553470A (zh) | 抗菌的喹啉衍生物 | |
CN109790165A (zh) | 抗微生物剂及其制备和使用方法 | |
CN109942546A (zh) | 喹诺酮嘧啶类化合物及其制备方法和应用 | |
CN107427507A (zh) | 呼吸器官感染治疗剂 | |
CN101252927A (zh) | 作为抗菌剂的喹啉衍生物 | |
CN101553471B (zh) | 抗菌喹啉衍生物 | |
CN108658991A (zh) | 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途 | |
CN101225093B (zh) | 氨基糖苷类衍生物 | |
CN100569789C (zh) | 硫酸阿奇霉素和其应用及其冻干粉针剂和冻干粉针剂的制备方法 | |
CN106749213A (zh) | 一种具有1,2,4‑恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用 | |
CN101547906B (zh) | 抗菌喹啉衍生物 | |
CN104098588A (zh) | 一类三环喹诺酮衍生物及其制备方法和用途 | |
CN104254528B (zh) | 抗菌的喹啉衍生物 | |
CN110396090A (zh) | 咪唑醇类四氢黄连肟缀合物及其制备方法和应用 | |
CN108503585B (zh) | Penicilone B的氨基酸衍生物及其作为抗菌药物的应用 | |
CN110234323A (zh) | 具有抗菌活性的酮内酯 | |
CN104004003B (zh) | 头孢克肟衍生物及其制备方法和用途 | |
Thakare et al. | Zoliflodacin. DNA gyrase subunit B (GyrB)(bacterial) inhibitor, Treatment of uncomplicated gonorrhea | |
CN111135182A (zh) | 一种抗菌产品及其制备方法和应用 | |
CN104230920B (zh) | 一种四氢巴马丁季铵盐及其制备方法和用途 | |
KR101318181B1 (ko) | 항균제로서의 퀴놀린 유도체 | |
CN103467448A (zh) | 7-(3-氨基-4-烷氧亚胺基-1-哌啶基)-1-[(1r,2s)-2-氟环丙基]喹诺酮羧酸类化合物及其制备方法 | |
CN102342939B (zh) | 黄连素-苯乙酸类衍生物或其盐在制备治疗抗微生物药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd. Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA Patentee before: Xinglin Holding Co. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231218 Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA Patentee after: Xinglin Holding Co. Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd. |